CSL, Arcturus Therapeutics announce European Commission approval for Kostaive
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 14 2025
0mins
Approval of Kostaive: The European Commission has granted marketing authorization for Kostaive, a self-amplifying mRNA COVID-19 vaccine for individuals aged 18 and older, making it the first sa-mRNA COVID-19 vaccine approved in Europe.
Market Presence: Kostaive is already marketed in Japan and the European approval follows a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use on December 12, 2024, allowing its use across all EU member states and EEA countries.
Analyst Views on ARCT
Wall Street analysts forecast ARCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARCT is 30.57 USD with a low forecast of 7.00 USD and a high forecast of 72.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
6 Buy
3 Hold
0 Sell
Moderate Buy
Current: 7.590
Low
7.00
Averages
30.57
High
72.00
Current: 7.590
Low
7.00
Averages
30.57
High
72.00
About ARCT
Arcturus Therapeutics Holdings Inc. is a commercial mRNA medicines and vaccines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. The Company with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. It has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The Company's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
